Chicago-based Errant Gene Therapeutics has sued Third Rock Ventures and Bluebird Bio CEO Nick Leschly, alleging that the pair conspired to ‘kill’ a competing medical treatment.
Filed in Suffolk County Superior County in Massachusetts, plaintiff Errant claims that Errant Gen purchased exclusive rights to a gene therapy drug being developed by Memorial Sloan Kettering Cancer (MSKC) Center researcher Michael Sadelain, MD, PhD, in 2005. Both the biotech ventures are developing a rare blood disease treatment. Bluebird recently secured European approval for its drug, reports Becker’s Hospital Review. Third Rock (defendant) sought to license the vector, which was a key component of the drug being developed by Dr. Sadelain. Dr. Sadelain refused to abide by the 2010 terms.
Errant Gene signed the vector rights back to MSKC in 2011, but the plaintiff claims that Third Rock’s relationship with MSKC’s CEO Craig Thompson went to benefit Bluebird as Third Rock thereafter negotiated the rights for Bluebird.
The lawsuit essentially alleges that investor Third Rock is a proactive agent in not only going through actions to benefit its portfolio company Bluebird, but that the group conspired to d...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).